Shares of Transenterix Inc (NASDAQ:TRXC) have earned a consensus broker rating score of 2.00 (Buy) from the four brokers that cover the company, Zacks Investment Research reports. Two analysts have rated the stock with a hold rating and two have given a strong buy rating to the company. Transenterix’s rating score has declined by 33.3% from 90 days ago as a result of various analysts’ upgrades and downgrades.

Analysts have set a 1 year consensus price objective of $2.82 for the company and are forecasting that the company will post ($0.11) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Transenterix an industry rank of 179 out of 265 based on the ratings given to its competitors.

A number of equities research analysts have recently issued reports on the company. B. Riley lowered Transenterix to a “neutral” rating and set a $0.70 price target for the company. in a research report on Tuesday, May 16th. Zacks Investment Research lowered Transenterix from a “buy” rating to a “hold” rating in a research report on Thursday, May 11th.

Transenterix (NASDAQ TRXC) traded up 21.538% during mid-day trading on Monday, hitting $0.632. 2,093,911 shares of the stock were exchanged. The company’s market capitalization is $93.87 million. The stock has a 50 day moving average price of $0.54 and a 200 day moving average price of $1.12. Transenterix has a 1-year low of $0.45 and a 1-year high of $2.33.

ILLEGAL ACTIVITY WARNING: “Analysts Anticipate Transenterix Inc (TRXC) to Announce ($0.11) Earnings Per Share” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at

In related news, Director Richard C. Pfenniger, Jr. purchased 100,000 shares of the company’s stock in a transaction dated Tuesday, May 16th. The stock was acquired at an average cost of $0.54 per share, for a total transaction of $54,000.00. Following the completion of the transaction, the director now directly owns 148,000 shares of the company’s stock, valued at $79,920. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Transenterix Company Profile

TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.

Get a free copy of the Zacks research report on Transenterix (TRXC)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Transenterix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix Inc and related companies with's FREE daily email newsletter.